COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 9 of 27 for:    "revance therapeutics"

Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03137407
Recruitment Status : Completed
First Posted : May 2, 2017
Last Update Posted : October 17, 2019
Information provided by (Responsible Party):
Revance Therapeutics, Inc.

Brief Summary:
The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.

Condition or disease Intervention/treatment Phase
Plantar Fasciitis Biological: Botulinum Toxins, Type A Biological: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 59 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
Actual Study Start Date : June 12, 2017
Actual Primary Completion Date : February 20, 2018
Actual Study Completion Date : February 20, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Botox

Arm Intervention/treatment
Experimental: DaxibotulinumtoxinA 240 units
Botulinum Toxins, Type A Intramuscular Injection
Biological: Botulinum Toxins, Type A
Intramuscular injection
Other Name: DaxibotulinumtoxinA

Placebo Comparator: Placebo
Placebo Intramuscular Injection
Biological: Placebo
Intramuscular injection

Primary Outcome Measures :
  1. Reduction in the visual analog scale (VAS) for pain for the foot [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. Reduction in VAS for pain for the foot [ Time Frame: Up to 16 weeks ]
  2. American Orthopaedic Foot and Ankle Score (AOFAS) [ Time Frame: Up to 16 weeks ]
  3. Patient Reported Outcomes [ Time Frame: Up to 16 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent, including authorization to release health information
  • Male or female subjects 18 to 65 years of age with diagnosis of plantar fasciitis
  • Persistent heel pain for more than three months
  • Women of child bearing potential must have negative pregnancy test at Screening and Injection Visits and must use an effective method of birth control during the course of the study

Exclusion Criteria:

  • Previous surgery on the midfoot or hindfoot
  • Neuromuscular disease
  • Systemic muscle weakness
  • Planning a pregnancy during the study
  • Current enrollment in an investigational drug or device study or participation in such a study within the last 30 days prior to first visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03137407

Layout table for location information
United States, Georgia
Village Podiatry Centers
Duluth, Georgia, United States, 30096
United States, Illinois
Weil Foot and Ankle Institute
Des Plaines, Illinois, United States, 60016
United States, Kansas
Kansas City Bone & Joint Clinic
Overland Park, Kansas, United States, 66211
United States, North Carolina
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States, 27157
United States, Texas
Element Research Group
San Antonio, Texas, United States, 78212
Sponsors and Collaborators
Revance Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Revance Therapeutics, Inc. Identifier: NCT03137407    
Other Study ID Numbers: 1720201
First Posted: May 2, 2017    Key Record Dates
Last Update Posted: October 17, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Revance Therapeutics, Inc.:
heel pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Fasciitis, Plantar
Musculoskeletal Diseases
Foot Diseases
Botulinum Toxins
Botulinum Toxins, Type A
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents